These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31649976)

  • 1. Hyaluronidase injections for treatment of symptomatic pansclerotic morphea-induced microstomia.
    Abbas LF; Coias J; Jacobe HT; Nijhawan RI
    JAAD Case Rep; 2019 Oct; 5(10):871-873. PubMed ID: 31649976
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyaluronidase Injections for Oral Microstomia in Systemic Sclerosis and Mixed Connective Tissue Disease.
    Min MS; Goldman N; Mazori DR; Guo LN; Vleugels RA; LaChance AH
    JAMA Dermatol; 2023 Dec; 159(12):1393-1395. PubMed ID: 37851438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disabling pansclerotic morphea of children.
    Diaz-Perez JL; Connolly SM; Winkelmann RK
    Arch Dermatol; 1980 Feb; 116(2):169-73. PubMed ID: 7356347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pansclerotic morphea with a rapidly fatal outcome in an 11-year-old girl].
    Hardy J; Audouin-Pajot C; Abid A; Chiotasso D; Coustets B; Suc A; Timsit P; Mouthon L; Mazereeuw-Hautier J
    Ann Dermatol Venereol; 2016 Dec; 143(12):836-840. PubMed ID: 27496274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pansclerotic morphea: A male child with hemiatrophy of lower limb.
    Dasgupta MK; Patra C; Sarkar S; Das S
    Indian Dermatol Online J; 2014 Apr; 5(2):170-2. PubMed ID: 24860754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pansclerotic morphea treated with UVA: a case report.
    Yildirim M; Baysal V; Aridogan BC; Kesici D; Erturan I
    J Dermatol; 2003 Aug; 30(8):625-7. PubMed ID: 12928533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronidase as a Successful Treatment Modality for Scleroderma-Induced Microstomia.
    Chopra D; Brehm JE; Morrison B
    Dermatol Surg; 2022 Sep; 48(9):1014-1015. PubMed ID: 35834642
    [No Abstract]   [Full Text] [Related]  

  • 8. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
    Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistence of morphea and systemic sclerosis.
    Soma Y; Tamaki T; Kikuchi K; Abe M; Igarashi A; Takehara K; Ishibashi Y
    Dermatology; 1993; 186(2):103-5. PubMed ID: 8428037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Squamous cell carcinoma in pansclerotic morphea of childhood.
    Wollina U; Buslau M; Weyers W
    Pediatr Dermatol; 2002; 19(2):151-4. PubMed ID: 11994182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous and subcutaneous inflammatory sclerosis syndromes.
    Doyle JA; Connolly SM; Winkelmann RK
    Arch Dermatol; 1982 Nov; 118(11):886-90. PubMed ID: 7138043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disabling pansclerotic morphea of childhood with extracutaneous manifestations.
    Kura MM; Jindal SR
    Indian J Dermatol; 2013 Mar; 58(2):159. PubMed ID: 23716826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological study of 81 cases of localized and systemic scleroderma.
    Succaria F; Kurban M; Kibbi AG; Abbas O
    J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e191-6. PubMed ID: 22620486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the classification and treatment of localized scleroderma.
    Bielsa Marsol I
    Actas Dermosifiliogr; 2013 Oct; 104(8):654-66. PubMed ID: 23948159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodular morphea (NM): report of a case of concurrent NM and morphea profunda associated with limited type systemic sclerosis, and overview and definition for NM.
    Ohata C; Yasunaga M; Tsuruta D; Ishii N; Hamada T; Dainichi T; Karashima T; Nakama T; Hashimoto T
    Eur J Dermatol; 2013; 23(1):87-93. PubMed ID: 23400240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disabling pansclerotic morphea of childhood and hypogammaglobulinemia: a curious association.
    Devidayal ; Singh S; Kumar L; Radotra BD
    Rheumatol Int; 2002 Jan; 21(4):158-60. PubMed ID: 11843172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronidase Treatment of Scleroderma-Induced Microstomia.
    Melvin OG; Hunt KM; Jacobson ES
    JAMA Dermatol; 2019 Jul; 155(7):857-859. PubMed ID: 31141116
    [No Abstract]   [Full Text] [Related]  

  • 18. Disabling pansclerotic morphea: clinical presentation in two adults.
    Maragh SH; Davis MD; Bruce AJ; Nelson AM
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S115-9. PubMed ID: 16021158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against antigens related to scleroderma in a cohort of patients with morphea.
    Arisi M; Cavazzana I; Cerutti ME; Ferrari F; Carabellese N; Rossi MT; Tincani A; Calzavara-Pinton P; Franceschini F
    G Ital Dermatol Venereol; 2018 Aug; 153(4):451-458. PubMed ID: 27706114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies.
    Fett N
    Clin Dermatol; 2013; 31(4):432-437. PubMed ID: 23806160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.